Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Registration Number
- NCT06435858
- Lead Sponsor
- Cantonal Hospital Graubuenden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria:<br><br> - <br><br> - Patients 18-75 years old with ADPKD, defined according to international<br> diagnostic and classification criteria14, treated at Cantonal Hospital<br> Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of<br> baseline treatment with the vasopressin receptor antagonist Tolvaptan<br><br> - Informed consent as documented by signature<br><br>Exclusion Criteria:<br><br> - <br><br> - renal replacement therapy or kidney allograft recipient<br><br> - chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2)<br><br> - patients younger 18 years of age<br><br> - Diabetes mellitus type 1<br><br> - recurrent urinary tract infections (UTI) defined as more than 3 infections requiring<br> antibiotic treatment or over 1 requiring hospitalization/year.<br><br> - Patients with uncontrolled hypertension (defined as ambulatory systolic BP over<br> 180mmHg), liver cirrhosis (Child Pugh B and C)<br><br> - Patients not able or not willing to stop the following medications during the study<br> period of participation in the trial:<br><br> - Thiazide diuretics<br><br> - Carbonic anhydrase inhibitors<br><br> - Sodium bicarbonate<br><br> - 1, 25 (OH) vitamin D (calcitriol)<br><br> - Bisphosphonate, denosumab, teriparatide<br><br> - Pregnant or lactating women<br><br> - Known allergy to study drug<br><br> - Inability to understand and follow the protocol
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcome
- Secondary Outcome Measures
Name Time Method Secondary Outcome